Loading
A phase 2 trial of Pafolacianine in Prostate cancer, run by Indiana University, completed.
CYTALUX™for the Intraoperative Imaging of Prostate Cancer is a phase 2 interventional study registered as NCT06434909 by Indiana University, with 9 participants recorded, started 2024-09-19 and reaching its primary completion in 2025-09-04. Interventions recorded: Cytalux™ (pafolacianine) for fluorescent imaging, Image Guided Surgery. Conditions recorded: Prostate Cancer.
Linked to the drug Pafolacianine because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Pafolacianine and the tag pipeline.
Shares Pafolacianine and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.